SECOND]1 AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 22nd, 2024 • Bicara Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
This [Second]2 Amended and Restated Employment Agreement (“Agreement”) is made between Bicara Therapeutics Inc., a Delaware corporation (the “Company”), and [Name] (the “Executive”), and is effective commencing on [ ] (the “Effective Date”). Except with respect to the Equity Documents and Restrictive Covenants Agreement (both as defined below) and subject to Section 11 below, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment agreement between the Executive and the Company dated [ ], [as amended by the First Amendment to Employment Agreement dated [ ],and the Amended and Restated Employment Agreement dated [ ]]3 (collectively, the “Prior Agreements”), and (ii) any other offer letter, employment agreement or severance agreement.
CONTRACT TRANSFER AND LICENSE AGREEMENTContract Transfer and License Agreement • June 10th, 2024 • Bicara Therapeutics Inc. • Pharmaceutical preparations • London
This Contract Transfer and License Agreement (the “License Agreement” or “Agreement”) is made on October 1, 2019 by and between Biocon Limited, a company duly incorporated under the laws of India having a principal place of business at 20th KM., Hosur Road, Electronics City P.O, Bangalore-560100, India (“Biocon”) and Bicara Therapeutics Inc., a company duly incorporated under the laws of Delaware having a principal place of business at 245 Main Street, Cambridge, MA 02142, County of Middlesex (“Bicara”).
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • August 22nd, 2024 • Bicara Therapeutics Inc. • Pharmaceutical preparations • Delaware
THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of December 6, 2023, by and among Bicara Therapeutics Inc., a Delaware corporation (the “Company”), and the Investors (as defined below).
OFFICE LEASE AGREEMENT BY AND BETWEEN COLUMBIA REIT – 116 HUNTINGTON, LLC a Delaware limited liability company AND BICARA THERAPEUTICS INC., a Delaware corporation 116 Huntington Avenue Boston, Massachusetts 02116Office Lease Agreement • June 10th, 2024 • Bicara Therapeutics Inc. • Pharmaceutical preparations
THIS OFFICE LEASE AGREEMENT (this “Lease”) is dated as of August 16, 2023 (“Execution Date”), by and between COLUMBIA REIT – 116 HUNTINGTON, LLC, a Delaware limited liability company (“Landlord”), and BICARA THERAPEUTICS INC., a Delaware corporation (“Tenant”).
Clinical Trial Collaboration and Supply Agreement by and among MSD International GmbH, MSD International Business GmbH, and Collaborator (as defined below) Clinical Trial Collaboration and Supply Agreement—Information SheetCollaboration and Supply Agreement • June 10th, 2024 • Bicara Therapeutics Inc. • Pharmaceutical preparations • New York
This Clinical Trial Collaboration and Supply Agreement is entered into as of the Effective Date, by and among MSD International GmbH (“MSDIG”), MSD International Business GmbH (“MSDIB”, and collectively with MSDIG, “MSD”), each having a place of business at [***], and Collaborator (as defined below), having a place of business at the Collaborator Address (as defined below). MSD and Collaborator are each referred to herein individually as a “Party” and collectively as the “Parties”.
